A lipid-soluble iron chelator alters cell cycle regulatory protein binding in breast cancer cells compared to normal breast cells

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 3, 2007, Pages 193-200

  Pahl, Paula M B ^a   Reese, Sara M ^a   Horwitz, Lawrence D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Apoptosis; Breast cancer; Cell cycle; Desferri exochelin; Iron; Iron chelation; P21; P53

Indexed keywords

CHELATING AGENT; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DESFERRI EXOCHELIN; IRON; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CELL CULTURE; CELL CYCLE REGULATION; CHELATION; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIPID SOLUBILITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

APOPTOSIS; BREAST; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IRON CHELATING AGENTS; PEPTIDES, CYCLIC; PROTEIN BINDING; SOLUBILITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34249085249     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pahl PMB, Horwitz L. Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest, 23: 683-691, 2006.
2. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev, 57: 547-583, 2005.
3. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol. Biochem, 11: 173-186, 2001.
4. Pahl PMB, Horwitz MA, Horwitz KB, Horwitz LD. Desferri-exochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. Breast Cancer Res Treat, 69: 69-79, 2001.
5. Gobin J, Moore CH, Reeve JR Jr, Wong DK, Gibson BW, Horwitz MA. Iron acquisition by Mycobacterium tuberculosis: Isolation and characterization of a family of iron-binding exochelins. Proc Natl Acad Sci USA, 92: 5189-5193, 1995.
6. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst, 51: 1409-1416, 1973.
7. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY. D-type cyclin-dependent kinase activity in mammalian cells Mol Cell Biol, 14: 2066-2076, 1994.
8. Sheaff RJ. Regulation of mammalian cyclin-dependent kinase 2. Meth Enzymol. 283: 173-193, 1997.
9. Porter DC, Keyomarsi K. Novel splice variants of cyclin E with altered substrate specificity. Nucl Acids Res, 28: E101, 2000.
10. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res, 60:481-489, 2000.
11. Lee M-H, Yang H-Y. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci, 58: 1907-1922, 2001.
12. 2 tension. Proc Natl Acad Sci USA, 92: 5510-5514, 1995.
13. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1α in common cancers and their metastases. Cancer Res, 59: 5830-5835, 1999.
14. Chong TW, Horwitz LD, Moore JW, Sowter HM, Harris AL. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. Cancer Res, 62: 6924-6927, 2002.
15. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature, 392: 405-408 1998.
16. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. Toward maintaining the genome: DNA damage and replication checkpoints. Ann Rev Genet, 36: 617-656, 2002.
17. Malkin D. The role of p53 in human cancer. J Neuro-Oncol, 51: 231-243, 2001.
18. Pahl PMB, Yan XD, Hodges YK, Rosenthal, Horwitz MA, Horwitz LD. An exochelin of Mycobacterium tuberculosis reversibly arrests growth of human vascular smooth muscle cells in vitro. J Biol Chem, 275: 17821-17826, 2000.
19. Horwitz LD, Sherman NA, Kong Y, Pike AW, Gobin J, Fennessey PV, Horwitz MA. Lipophilic siderophores of Mycobacterium tuberculosis prevent cardiac reperfusion injury. Proc National Acad Sciences USA, 95: 5263-5269, 1998.
20. Hodges YK, Reese SM, Pahl PMB, Horwitz LD. Paradoxical Effects of Iron Chelation on Growth of Vascular Endothelial Cells. J Cardiovasc Pharmacol, 45: 539-544, 2005.
21. Jordan A, Reichard P. Ribonucleotide reductases. Annu Rev Biochem, 67: 71-981998.
22. Hodges YK, Antholine WE, Horwitz LD. Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins. Biochem Biophys Res Commun, 315: 595-598, 2004.
23. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: cell cycle arrest versus apoptosis. Toxicology, 181-182: 475-481, 2002.
24. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Rad Biol Med, 28: 1387-1404, 2000.
25. El-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol, 8: 345-357, 1998.
26. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev, 14: 34-44, 2000.
27. O'Brate A, Giannakakou P. The importance of p53 location: nuclear or cytoplasmic zip code?. Drug Resist Updates, 6: 313-322, 2003.
28. Liang SX, Richards DR. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis, 24: 1601-1614, 2003.